Vantage Consulting Group’s Royalty Pharma RPRX Stock Holding History

Vantage Consulting Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57,500	Closed	-$1.56M	–	216
2023 Q3	$1.56M	Sell	57,500 -593,190	-91%	-$17.6M	1.05%	6
2023 Q2	$20M	Sell	650,690 -371,504	-36%	-$12.6M	11.51%	2
2023 Q1	$36.8M	Hold	1,022,194	–	–	20.91%	2
2022 Q4	$35.5M	Hold	1,022,194	–	–	20.94%	2
2022 Q3	$41.1M	Sell	1,022,194 -29,701	-3%	-$1.27M	24%	2
2022 Q2	$44.2M	Sell	1,051,895 -1,675,959	-61%	-$68.7M	24.8%	2
2022 Q1	$106M	Sell	2,727,854 -1,873,298	-41%	-$73.6M	41.47%	1
2021 Q4	$183M	Sell	4,601,152 -3,261,390	-41%	-$127M	49.3%	1
2021 Q3	$284M	Sell	7,862,542 -1,439,903	-15%	-$56M	60.85%	1
2021 Q2	$381M	Buy	9,302,445 +596,894	+7%	+$25.4M	66.33%	1
2021 Q1	$380M	Sell	8,705,551 -12,771,731	-59%	-$606M	76.23%	1
2020 Q4	$1.07B	Buy	+21,477,282	New	+$911M	87.53%	1

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vantage Consulting Group's RPRX Position: Q4 2023 in Review

Vantage Consulting Group sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 57,500 shares — an estimated $1.56M sold.

Vantage Consulting Group first reported a position in RPRX in Q4 2020 and held it in 12 quarters. The position peaked at $1.07B in Q4 2020. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Vantage Consulting Group reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
Vantage Consulting Group sold 57,500 Royalty Pharma shares in Q4 2023, an estimated $1.56M.
Vantage Consulting Group first reported a position in Royalty Pharma in Q4 2020 and held it in 12 quarters.
Vantage Consulting Group's Royalty Pharma position peaked at $1.07B in Q4 2020.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Vantage Consulting Group's 13F filing for Q4 2023, filed 14 Feb 2024.